心房颤动与缺血性卒中的预防
被引量：3
Atrial Fibrillation and Prevention of Ischemic Stroke
摘要
心房颤动（AF）作为缺血性卒中的重要危险因素已经得到确认。但在卒中预防实践中，如何正确选择AF患者进行抗凝治疗，哪些AF患者适用抗凝治疗，哪种抗凝强度更加合理，以及如何权衡长期抗凝治疗的风险和效益，均存在一定的争论。文章对此进行了分析。
出处
《国际脑血管病杂志》
2008年第5期393-400,共8页
International Journal of Cerebrovascular Diseases
参考文献35
-
1Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis, 2008, 25 : 26 - 32.
-
2Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke, 2008, 39:1901 - 1910.
-
3Taggar JS, Watson T, Lip GY. Can patients with atrial fibrillation be optimally risk stratified for stroke and thromboembolism? Stroke, 2008, 39:e24 - e25.
-
4Wyse DG. Anticoagulation in atrial fibrillation: a contemporary viewpoint. Heart Rhythm, 2007, 4:S34 - S39.
-
5Stroke Risk in Atrial Fibrillation Working Croup. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 2007, 69:546 -554.
-
6Lip GY. The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited. Stroke, 2008, 39:1406 - 1408.
-
7Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation, 2004, 110:2287 -2292.
-
8Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke, 2007, 38:2459 - 2463.
-
9Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006, 114:e257 - e354.
-
10National Collaborating Centre for Chronic Conditions. Atrial fibrillation. National clinical guideline for management in primary and secondary care. London (UK): Royal College of Physicians, 2006.
同被引文献86
-
1Sudlow M,Thomson R,Thwaites B,et al.Prevalence of atrial fibrillation and eligibility for anticoagulants in the community Lancet, 1998,352: 1167- 1171.
-
2Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management ard stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001,285: 2370-2375.
-
3Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 2007, 69: 546-554.
-
4Olsson SB; Executixe Steering Committee of the SPORTIF Ⅲ Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ): rardomised controlled trial. Lancet, 2003, 362: 1691-1698.
-
5Albers GW, Diener HC, Frison L, et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular: atrial fibrillatiorr a randomized trial. JAMA, 2005, 293: 690-698.
-
6Hylek EM, Frison L, Henault LE, et al. Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation Potential Insights Into Risk From a Comparative Analysis of SPORTIF Ⅲ Versus SPORTIF V. Stroke, 2008, 39: 3009-3014.
-
7White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulation control. Arch Intern Med, 2007, 167: 239-245.
-
8Zehnder BS, Schaer BA, Jeker U, et al. Atrial fibrillation: estimated excess rate of stroke due to lacking adherence to guidelines. Swiss Med Wkly, 2006, 136: 757-760.
-
9Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009, 40: 235-240.
-
10Singer DE, Albers GW, Dalen JE, et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, 2008, 133: 546S-592S.
二级引证文献8
-
1刘杰斌,刘晓华.急性脑血管病合并心血管病心电图异常临床分析[J].吉林医学,2011,32(14):2741-2742. 被引量：8
-
2陈明志.急性脑血管病伴发心血管异常32例临床分析[J].现代诊断与治疗,2013,24(16):3741-3741.
-
3罗叶婷,李广生.动脉粥样硬化与非瓣膜性房颤缺血性脑卒中[J].赣南医学院学报,2014,34(6):989-992. 被引量：1
-
4吴乐程,鲍德国.非瓣膜性心房颤动脑卒中危险因素的临床分析[J].健康研究,2015,35(3):287-289. 被引量：4
-
5林文海,陈曦,湛晴宇.抗栓治疗在低危和中危非瓣膜性房颤中的疗效分析[J].黑龙江医学,2016,40(8):707-708.
-
6崔红莉,马大亮.非瓣膜性房颤患者缺血性脑卒中临床危险因素研究[J].中外医疗,2017,36(15):1-3. 被引量：3
-
7符霞,陈晓敏.预测非瓣膜性心房颤动患者发生缺血性脑卒中的危险因素分析[J].中西医结合心血管病电子杂志,2019,7(3):20-21. 被引量：2
-
8刘红阳,王丽,周雁花.非瓣膜性房颤患者缺血性脑卒中临床危险因素研究[J].新疆医学,2019,49(9):908-910. 被引量：4
-
1郝宝利,杨明会.喹硫平联合丙戊酸镁缓释片治疗老年痴呆伴精神行为症状对照研究[J].临床心身疾病杂志,2016,22(2):24-26. 被引量：10
-
2对管理新发现房颤患者的建议[J].中华全科医师杂志,2009,8(9):652-652.
-
3郝长宁,陈颖敏.老年心房颤动患者华法林治疗的效果与风险[J].中国心脏起搏与心电生理杂志,2010,24(3):260-262. 被引量：7
-
4胡发明,过鑫昌.房颤病人的卒中预防[J].国外医药（合成药．生化药．制剂分册）,2001,22(4):218-218.
-
5范书平,张国平,张宏力,程丽容,甄素平,张建容,吴静.心房颤动诱因及卒中预防——附130例临床观察[J].实用心脑肺血管病杂志,2007,15(9):693-694.
-
6郭艺芳.加强心房颤动患者的卒中预防[J].内科理论与实践,2011,6(6):412-415.
-
7赵军红.探究房颤患者卒中预防的重要性[J].世界最新医学信息文摘,2015,15(62).
-
8董可辉.贯彻分层理念,发挥他汀的卒中预防优势[J].中国社区医师,2009,25(4):11-12. 被引量：2
-
9沈洁玲,张新江,陶丽红,唐铁钰.心房颤动患者卒中预防中的抗凝治疗：安全性和依从性[J].国际脑血管病杂志,2016,24(1):68-74. 被引量：3
-
10Karjalainen P.P.,Porela P.,Ylitalo A.,王海玲.冠状动脉支架置入术后抗血小板-华法林联合治疗的安全性和有效性[J].世界核心医学期刊文摘（心脏病学分册）,2007,0(8):39-40.
